Solventum (SOLV) Rated Buy by Jefferies After Earnings Beat

Solventum Corporation (NYSE:SOLV) ranks among the recent spin-off companies that hedge funds are piling into. On March 20, CIBC reiterated its Outperformer rating on Solventum Corporation (NYSE:SOLV) and its $37 price target. The firm believes the company’s 2026 forecast, which is slightly higher than consensus estimates, includes some caution, notably on gross margins.

CIBC stated that management might use increased balance sheet capacity for mergers and acquisitions to increase scale, footprint, and service offerings, with deals potentially occurring in 2026.

Meanwhile, following the company’s full-year results, Jefferies reiterated its Buy rating and $32 price target for Solventum Corporation (NYSE:SOLV). The company slightly surpassed top-line expectations for its fiscal year earnings, while adjusted EBITDA came in slightly below Jefferies’ forecast, though above consensus.

The firm said the fiscal 2026 forecast is prudent but fair, generally in line with consensus, even though it assumes a lower gross margin than Jefferies estimates.

Solventum Corporation (NYSE:SOLV) is a healthcare company that develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the US and internationally. It has three segments: Medsurg, Dental Solutions, and Health Information Systems.

While we acknowledge the risk and potential of SOLV as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than SOLV and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.